Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm : conditioning intensity matters
© 2022. The Author(s), under exclusive licence to Springer Nature Limited..
Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could improve outcome in patients with BPDCN, the individual contributions of conditioning and graft-versus-tumor (GVT) effects to HCT success are undefined. We present a retrospective study of 162 adult patients who underwent a first HCT (allogeneic 146, autologous 16) between 2009 and 2017, and were registered with the EBMT. Median age was 57 (range 20-73) years, and disease status at HCT was first complete remission (CR1) in 78%. Among patients receiving allogeneic HCT (alloHCT), myeloablative conditioning (MAC), reduced intensity conditioning (RIC) and in-vivo T-cell depletion (TCD) were used in 54%, 46%, and 59% respectively. Total body irradiation (TBI) was the conditioning backbone in 61% of MAC and 26% of RIC transplants. One-year overall survival (OS) and progression-free survival (PFS) rates were comparable after alloHCT and autologous HCT (autoHCT). Among alloHCT recipients, MAC with TBI significantly improved OS and PFS, independently of CR1, age, Karnofsky index and TCD. Accordingly, MAC (ideally based on TBI) should be preferred for alloHCT recipients with BPDCN. In patients who are not elegible for MAC alloHCT, autoHCT could be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Leukemia - 37(2023), 2 vom: 22. Feb., Seite 465-472 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bruch, Peter-Martin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.02.2023 Date Revised 30.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41375-022-01782-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350617368 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350617368 | ||
| 003 | DE-627 | ||
| 005 | 20231226045412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-022-01782-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350617368 | ||
| 035 | |a (NLM)36550212 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bruch, Peter-Martin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm |b conditioning intensity matters |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2023 | ||
| 500 | |a Date Revised 30.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could improve outcome in patients with BPDCN, the individual contributions of conditioning and graft-versus-tumor (GVT) effects to HCT success are undefined. We present a retrospective study of 162 adult patients who underwent a first HCT (allogeneic 146, autologous 16) between 2009 and 2017, and were registered with the EBMT. Median age was 57 (range 20-73) years, and disease status at HCT was first complete remission (CR1) in 78%. Among patients receiving allogeneic HCT (alloHCT), myeloablative conditioning (MAC), reduced intensity conditioning (RIC) and in-vivo T-cell depletion (TCD) were used in 54%, 46%, and 59% respectively. Total body irradiation (TBI) was the conditioning backbone in 61% of MAC and 26% of RIC transplants. One-year overall survival (OS) and progression-free survival (PFS) rates were comparable after alloHCT and autologous HCT (autoHCT). Among alloHCT recipients, MAC with TBI significantly improved OS and PFS, independently of CR1, age, Karnofsky index and TCD. Accordingly, MAC (ideally based on TBI) should be preferred for alloHCT recipients with BPDCN. In patients who are not elegible for MAC alloHCT, autoHCT could be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Dietrich, Sascha |e verfasserin |4 aut | |
| 700 | 1 | |a Finel, Herve |e verfasserin |4 aut | |
| 700 | 1 | |a Boumendil, Ariane |e verfasserin |4 aut | |
| 700 | 1 | |a Greinix, Hildegard |e verfasserin |4 aut | |
| 700 | 1 | |a Heinicke, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Bethge, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Beelen, Dietrich |e verfasserin |4 aut | |
| 700 | 1 | |a Schmid, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Castagna, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Scheid, Christof |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer-Eckart, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Bittenbring, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Finke, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Sengeloev, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Heiblig, Mael |e verfasserin |4 aut | |
| 700 | 1 | |a Cornelissen, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Chevallier, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Mohty, Mohamad |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Montoto, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Dreger, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d 1989 |g 37(2023), 2 vom: 22. Feb., Seite 465-472 |w (DE-627)NLM012593788 |x 1476-5551 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:2 |g day:22 |g month:02 |g pages:465-472 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41375-022-01782-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 2 |b 22 |c 02 |h 465-472 | ||